The impact of the availability of prevention studies on the desire to undergo predictive testing in persons at risk for autosomal dominant Alzheimer's disease.
about
Ethics of genetic and biomarker test disclosures in neurodegenerative disease prevention trialsA survey of attitudes toward clinical trials and genetic disclosure in autosomal dominant Alzheimer's disease.Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trialsA Survey of Knowledge and Views Concerning Genetic and Amyloid PET Status DisclosureConceptualization and assessment of vulnerability in a complex international Alzheimer's research study.
P2860
The impact of the availability of prevention studies on the desire to undergo predictive testing in persons at risk for autosomal dominant Alzheimer's disease.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 19 July 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The impact of the availability ...... dominant Alzheimer's disease.
@en
The impact of the availability ...... dominant Alzheimer's disease.
@nl
type
label
The impact of the availability ...... dominant Alzheimer's disease.
@en
The impact of the availability ...... dominant Alzheimer's disease.
@nl
prefLabel
The impact of the availability ...... dominant Alzheimer's disease.
@en
The impact of the availability ...... dominant Alzheimer's disease.
@nl
P2093
P2860
P1476
The impact of the availability ...... l dominant Alzheimer's disease
@en
P2093
Ana Isabel Alvarez-Retuerto
David Wharton
Jenny Brook
John M Ringman
Joshua D Grill
Megan Hooper
Michelle Fox
Yaneth Rodriguez-Agudelo
P2860
P304
P356
10.1016/J.CCT.2013.07.006
P407
P577
2013-07-19T00:00:00Z